About anixa biosciences - ANIX
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The CAR-T Therapeutics segment is involved in the development of immuno-therapy drugs against cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
ANIX At a Glance
Anixa Biosciences, Inc.
3150 Almaden Expressway
San Jose, California 95118
| Phone | 1-408-708-9808 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -12,554,000.00 | |
| Sector | Health Technology | Employees | 5 | |
| Fiscal Year-end | 10 / 2025 | |||
| View SEC Filings |
ANIX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.635 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.586 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.003 |
ANIX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,510,800.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ANIX Liquidity
| Current Ratio | 8.545 |
| Quick Ratio | 8.545 |
| Cash Ratio | 7.97 |
ANIX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -53.293 |
| Return on Equity | -56.632 |
| Return on Total Capital | -62.056 |
| Return on Invested Capital | -56.219 |
ANIX Capital Structure
| Total Debt to Total Equity | 1.16 |
| Total Debt to Total Capital | 1.147 |
| Total Debt to Total Assets | 1.075 |
| Long-Term Debt to Equity | 1.015 |
| Long-Term Debt to Total Capital | 1.003 |
Anixa Biosciences in the News
Breast cancer vaccine could prevent most aggressive form of disease from reoccurring
Scientists are currently testing a vaccine that could prevent the reoccurrence of triple-negative breast cancer, the most aggressive form of the disease.